⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30699839 | 0.73 | — | — | |
| SCHEMBL30426939 | 0.72 | — | — | |
| SCHEMBL24663879 | 0.72 | — | — | |
| SCHEMBL25298536 | 0.72 | POLB (0.31) | — | |
| SCHEMBL30157376 | 0.72 | POLB (0.31) | — | |
| SCHEMBL29680399 | 0.71 | — | — | |
| SCHEMBL22220706 | 0.71 | — | — | |
| SCHEMBL31491019 | 0.69 | — | — | |
| SCHEMBL30699763 | 0.68 | — | — | |
| SCHEMBL22208112 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-4262807-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230077225-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| US-20230072276-A1 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| US-11453683-B1 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2022-09-27 | — | — | US | disclosed |
| WO-2022132200-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |